|
Columbia University Medical Center researchers discover potential mechanism for tumor growth
December 16, 2005Researchers at Columbia University Medical Center have identified an inherent feature of stem and progenitor cells that may promote initiation and progression of cancerous tumors.
In a study published in the December issue of Cancer Cell, the team showed that stem and progenitor cells are susceptible to a specific error during cell division that can result in severe chromosomal defects. This susceptibility may explain how a tumor-initiating cell, also known as a cancer stem cell, arises from a normal cell. It may also explain how a cancer stem cell acquires additional mutations that increase tumor malignancy.
According to Timothy Bestor, Ph.D., and Marc Damelin, Ph.D., of Columbia University College of Physicians and Surgeons, understanding the nature of cancer stem cells could result in new therapies that specifically target those cells, which are thought to be the driving force of tumor progression.
The process of cell division is closely monitored by the cell, because a mistake can result in a cancer-causing chromosome abnormalities. Typically during cell division, cells monitor quality control with a series of checkpoints. One such checkpoint confirms that the cell's chromosomes have been disentangled before they are to be pulled apart in mitosis, to ensure that the chromosomes will be separated appropriately.
The Columbia researchers found, however, that stem and progenitor cells are deficient in this checkpoint and will divide even if the chromosomes are entangled. All three cell types tested by the researchers-mouse embryonic stem cells, mouse neural progenitor cells, and human bone marrow progenitor cells-attempted cell division with entangled chromosomes. The researchers think it likely that cancer stem cells, which closely resemble normal stem cells, have the same deficiency.
"The failure to untangle before dividing undoubtedly will lead to chromosomal defects," said Dr. Bestor, professor of genetics and development and the study's principal investigator. "Surviving cells may end up with too many chromosomes, they may lose chromosomes, or some chromosomes may get rearranged." These same types of chromosomal defects are the hallmark of cancer cells, and there are chromosomal abnormalities in all types of cancer.
"We may have found how a stem cell without any pre-existing mutation can become a cancer stem cell," said Dr. Damelin, a CUMC postdoctoral fellow of the Damon Runyon Cancer Research Foundation and the lead author on the study.
The research also points to potential obstacles involved with stem cell therapies. In the lab, stem cells are pushed to divide many times more than they normally would divide in an organism. The more stem cells divide, the more likely they are to acquire abnormal chromosome constitutions. Further research will be necessary to understand and address these risks.
Columbia University Medical Center
The process of cell division is closely monitored by the cell, because a mistake can result in a cancer-causing chromosome abnormalities. Typically during cell division, cells monitor quality control with a series of checkpoints. One such checkpoint confirms that the cell's chromosomes have been disentangled before they are to be pulled apart in mitosis, to ensure that the chromosomes will be separated appropriately.
The Columbia researchers found, however, that stem and progenitor cells are deficient in this checkpoint and will divide even if the chromosomes are entangled. All three cell types tested by the researchers-mouse embryonic stem cells, mouse neural progenitor cells, and human bone marrow progenitor cells-attempted cell division with entangled chromosomes. The researchers think it likely that cancer stem cells, which closely resemble normal stem cells, have the same deficiency.
"The failure to untangle before dividing undoubtedly will lead to chromosomal defects," said Dr. Bestor, professor of genetics and development and the study's principal investigator. "Surviving cells may end up with too many chromosomes, they may lose chromosomes, or some chromosomes may get rearranged." These same types of chromosomal defects are the hallmark of cancer cells, and there are chromosomal abnormalities in all types of cancer.
"We may have found how a stem cell without any pre-existing mutation can become a cancer stem cell," said Dr. Damelin, a CUMC postdoctoral fellow of the Damon Runyon Cancer Research Foundation and the lead author on the study.
The research also points to potential obstacles involved with stem cell therapies. In the lab, stem cells are pushed to divide many times more than they normally would divide in an organism. The more stem cells divide, the more likely they are to acquire abnormal chromosome constitutions. Further research will be necessary to understand and address these risks.
Columbia University Medical Center
Tumor Growth News and Current Tumor Growth Events RSSVitamin A pushes breast cancer to form blood vessel cells
Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth.
Researchers discover link between organ transplantation and increased cancer risk
Researchers have determined a novel mechanism through which organ transplantation often leads to cancer, and their findings suggest that targeted therapies may reduce or prevent that risk.
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
Blue light used to harden tooth fillings stunts tumor growth
A blue curing light used to harden dental fillings also may stunt tumor growth, Medical College of Georgia researchers say.
New Cancer Treatment Targets Both Tumor Cells and Blood Vessels
It takes more than one punch to fight tumors. Often, tumors have more than one way of surviving, and attacking the tumor alone is not enough.
Experimental anti-cancer synthetic molecule targets tumor cell growth and angiogenesis
A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19.
St. Jude finds young age may give survival advantage to children with certain brain tumors
St. Jude Children's Research Hospital investigators have shown that children under 3 years old who have a brain tumor called diffuse pontine glioma (DPG) appear to have a better outcome than older children with the same cancer.
Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers
Researchers at the University of Pennsylvania School of Medicine have shown how Argos, a fruit fly protein, acts as a ¡¥decoy' receptor, binding growth factors that promote the progression of cancer.
Avoiding Spleen Removal for Cooley's Anemia Sufferers
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia.
Estrogen Helps Drive Distinct, Aggressive Form of Prostate Cancer
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
More Tumor Growth News Articles
| © 2008 BrightSurf.com |